Anavex Life Sciences Corp.(AVXL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AVXL Anavex Life Sciences Corp.

交易中 04-28 09:43:32 EDT

3.31

+0.02

+0.46%

最高3.34	最低3.23	成交量6.28万
今开3.23	昨收3.29	日振幅3.34%
总市值3.06亿	流通市值2.74亿	总股本9,267万
成交额20.50万	换手率0.08%	流通股本8,305万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AVXL","market":"US","secType":"STK","nameCN":"Anavex Life Sciences Corp.","latestPrice":3.305,"timestamp":1777383806308,"preClose":3.29,"halted":0,"volume":62802,"delay":0,"changeRate":0.004559270516717363,"floatShares":83048051,"shares":92671758,"eps":-0.462642,"marketStatus":"交易中","change":0.015,"latestTime":"04-28 09:43:32 EDT","open":3.23,"high":3.3399,"low":3.23,"amount":204950.778687,"amplitude":0.033404,"askPrice":3.31,"askSize":499,"bidPrice":3.3,"bidSize":399,"shortable":3,"etf":0,"ttmEps":-0.462642,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1777406400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.29,"preHourTrading":{"tag":"盘前","latestPrice":3.25,"preClose":3.29,"latestTime":"09:29 EDT","volume":1030,"amount":3356.179913,"timestamp":1777382999999,"change":-0.04,"changeRate":-0.012158,"amplitude":0.106383},"postHourTrading":{"tag":"盘后","latestPrice":3.3606,"preClose":3.29,"latestTime":"19:18 EDT","volume":6529,"amount":21585.2594,"timestamp":1777331906149,"change":0.0706,"changeRate":0.021459,"amplitude":0.021459},"volumeRatio":2.262365,"impliedVol":0.9879,"impliedVolPercentile":0.5618},"requestUrl":"/m/hq/s/AVXL","defaultTab":"news","newsList":[{"id":"1175933470","title":"Anavex生命科学公司持续与欧洲药品管理局就口服Blarcamesine治疗早期阿尔茨海默病展开对话","url":"https://stock-news.laohu8.com/highlight/detail?id=1175933470","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175933470?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:35","pubTimestamp":1774870528,"startTime":"0","endTime":"0","summary":"Anavex生命科学公司正持续推进与欧洲药品管理局的沟通，围绕口服药物Blarcamesine在早期阿尔茨海默病治疗领域的应用展开深入探讨。此次对话标志着该公司在神经退行性疾病治疗研发方面的重要进展。\nBlarcamesine作为一种口服治疗候选药物，其作用机制针对阿尔茨海默病的病理生理过程。与欧洲监管机构的持续互动，体现了Anavex公司致力于为早期阿尔茨海默病患者开发创新疗法的承诺。\n该公司与欧洲药品管理局的交流涵盖多个关键议题，包括临床试验设计、疗效评估标准以及安全性数据要求等方面。这些讨论将为后续研发策略提供重要指导，助力推动该疗法在欧洲市场的监管审批进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191491014","title":"Anavex Life Sciences公布欧盟对Blarcamesine治疗早期阿尔茨海默病的监管审查进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1191491014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191491014?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:30","pubTimestamp":1774438221,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp. (AVXL) 近日披露了其在研药物Blarcamesine针对早期阿尔茨海默病于欧盟地区的监管审查最新动态。该公告旨在向投资者及市场通报这一重要治疗方案的审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184310305","title":"Anavex生命科学公布AD/PD 2026会议新数据：口服Blarcamesine疗效与早期阿尔茨海默病患者脑容量保留呈稳定关联","url":"https://stock-news.laohu8.com/highlight/detail?id=1184310305","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184310305?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:33","pubTimestamp":1774265630,"startTime":"0","endTime":"0","summary":"在AD/PD 2026国际会议上，Anavex生命科学公司发布了其AD-004二期b/三期临床试验的最新分析结果。数据显示，口服药物Blarcamesine的治疗效果与早期阿尔茨海默病患者脑容量保留程度之间存在持续一致性关联。该研究通过脑影像学检测发现，接受Blarcamesine治疗的患者群体相较于对照组，展现出更缓慢的脑萎缩速率。研究人员强调，脑容量指标与认知功能评分的协同改善趋势，为Blarcamesine延缓阿尔茨海默病进展的临床价值提供了客观生物学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139246758","title":"Anavex Life Sciences Corp：预计按当前现金消耗率 现金跑道可维持逾三年","url":"https://stock-news.laohu8.com/highlight/detail?id=1139246758","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139246758?lang=zh_cn&edition=full","pubTime":"2026-02-09 20:35","pubTimestamp":1770640510,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp（简称Anavex Life Sciences）近日透露，依照公司当前的现金消耗速度测算，其现有资金储备预计可支撑运营超过三年。这一数据为生物制药企业的持续研发提供了稳定的财务保障，展现出公司在资金管理方面的稳健态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195685429","title":"Anavex Life Sciences公布2026财年第一季度财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1195685429","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195685429?lang=zh_cn&edition=full","pubTime":"2026-02-09 20:31","pubTimestamp":1770640277,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp. (AVXL) 近日披露了其2026财年第一季度的财务报告，同时向市场同步了公司最新的业务动态。此次披露涵盖了公司在报告期内的财务状况及研发管线的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109729888","title":"Anavex Life Sciences Corp：将应监管机构要求提交现有Anavex2-73-Ad-004二期b/三期试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1109729888","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109729888?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:34","pubTimestamp":1767702858,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp宣布，将根据监管机构的要求，提交其Anavex2-73-AD-004二期b/三期临床试验项目中现有的数据。该举措旨在推进相关审查流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133705605","title":"Anavex Life Sciences关于Blarcamesine治疗早期阿尔茨海默病的欧盟监管审查最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1133705605","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133705605?lang=zh_cn&edition=full","pubTime":"2025-12-13 05:06","pubTimestamp":1765573571,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences关于Blarcamesine治疗早期阿尔茨海默病的欧盟监管审查最新进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588703523","title":"Anavex Life Sciences Corp.盘中异动 大幅拉升5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588703523","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588703523?lang=zh_cn&edition=full","pubTime":"2025-12-02 01:52","pubTimestamp":1764611576,"startTime":"0","endTime":"0","summary":"北京时间2025年12月02日01时52分，Anavex Life Sciences Corp.股票出现波动，股价急速上涨5.22%。Anavex Life Sciences Corp.股票所在的生物技术行业中，整体跌幅为1.53%。Anavex Life Sciences Corp.公司简介：Anavex Life Sciences Corp 是一家临床阶段的生物制药公司，致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物，这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202015256a71d5f89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202015256a71d5f89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101878650","title":"Anavex Life Sciences Corp：预计以当前现金使用率计算，现金流动性超过3年","url":"https://stock-news.laohu8.com/highlight/detail?id=1101878650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101878650?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:35","pubTimestamp":1764074110,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp：预计以当前现金使用率计算，现金流动性超过3年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188499538","title":"Anavex Life Sciences公布2025财年第四季度财务业绩并提供业务更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1188499538","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188499538?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:31","pubTimestamp":1764073883,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences公布了2025财年第四季度的财务结果，并提供了业务更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104025186","title":"Anavex Life Sciences Corp - Blarcamesine显示良好的安全性，无治疗相关死亡病例","url":"https://stock-news.laohu8.com/highlight/detail?id=1104025186","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104025186?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:33","pubTimestamp":1761737582,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp - Blarcamesine显示良好的安全性，无治疗相关死亡病例","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173376908","title":"Anavex Life Sciences宣布口服Blarcamesine的持续长期益处，与阿尔茨海默病神经影像倡议(Adni)对照组的下降情况相比","url":"https://stock-news.laohu8.com/highlight/detail?id=1173376908","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173376908?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:32","pubTimestamp":1761737540,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences宣布口服Blarcamesine的持续长期益处，与阿尔茨海默病神经影像倡议(Adni)对照组的下降情况相比","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518743902","title":"Anavex Life Sciences Corp.盘中异动 临近午盘股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518743902","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518743902?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:37","pubTimestamp":1741621049,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日23时37分，Anavex Life Sciences Corp.股票出现异动，股价急速上涨5.07%。截至发稿，该股报9.11美元/股，成交量29.0493万股，换手率0.34%，振幅7.84%。Anavex Life Sciences Corp.股票所在的生物技术行业中，整体涨幅为0.59%。Anavex Life Sciences Corp.公司简介：Anavex Life Sciences Corp 是一家临床阶段的生物制药公司，致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物，这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310233730a26a53ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310233730a26a53ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516860630","title":"Anavex Life Sciences Corp.盘中异动 急速拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516860630","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516860630?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:15","pubTimestamp":1741014921,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时15分，Anavex Life Sciences Corp.股票出现波动，股价急速拉升5.12%。截至发稿，该股报8.32美元/股，成交量17.146万股，换手率0.20%，振幅4.68%。Anavex Life Sciences Corp.股票所在的生物技术行业中，整体跌幅为0.09%。Anavex Life Sciences Corp.公司简介：Anavex Life Sciences Corp 是一家临床阶段的生物制药公司，致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物，这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303231521abe6419d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303231521abe6419d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512169464","title":"Anavex Life Sciences Corp.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512169464","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512169464?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:14","pubTimestamp":1739891677,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时14分，Anavex Life Sciences Corp.股票出现异动，股价急速上涨5.05%。截至发稿，该股报8.95美元/股，成交量14.6079万股，换手率0.17%，振幅4.58%。Anavex Life Sciences Corp.股票所在的生物技术行业中，整体涨幅为0.84%。Anavex Life Sciences Corp.公司简介：Anavex Life Sciences Corp 是一家临床阶段的生物制药公司，致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物，这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218231437a24ab690&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218231437a24ab690&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511748699","title":"Anavex Life Sciences Corp.盘中异动 股价大涨5.37%报8.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511748699","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511748699?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:48","pubTimestamp":1739544527,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时48分，Anavex Life Sciences Corp.股票出现异动，股价快速拉升5.37%。截至发稿，该股报8.93美元/股，成交量6.3362万股，换手率0.07%，振幅5.19%。Anavex Life Sciences Corp.股票所在的生物技术行业中，整体涨幅为0.30%。Anavex Life Sciences Corp.公司简介：Anavex Life Sciences Corp 是一家临床阶段的生物制药公司，致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物，这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224847abcf0a89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224847abcf0a89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169314471","title":"Anavex生命科学公司2025年第一季度GAAP每股收益$(0.14)好于预期$(0.19)，截至2024年12月31日公司现金及现金等价物为1.208亿美元，按当前现金使用率和范围预计可维持约4年","url":"https://stock-news.laohu8.com/highlight/detail?id=1169314471","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169314471?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:56","pubTimestamp":1739364973,"startTime":"0","endTime":"0","summary":"Anavex生命科学公司报告季度亏损为每股$，好于分析师预期的每股$，超出26.32%。这一结果较去年同期每股亏损$下降了27.27%。以上内容来自Benzinga Earnings专栏，原文如下：Anavex Life Sciences  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 26.32 percent. This is a 27.27 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Anavex生命科学公司2025年第一季度GAAP每股收益$(0.14)好于预期$(0.19)，截至2024年12月31日公司现金及现金等价物为1.208亿美元，按当前现金使用率和范围预计可维持约4年","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510132376","title":"Anavex Life Sciences(AVXL.US)：2025年Q1财报实现营收0美元，前值为0美元；每股收益为-0.14美元，前值为-0.11美元，预期值为-0.17美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510132376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510132376?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:44","pubTimestamp":1739364291,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences(AVXL.US)：2025年Q1财报实现营收0美元，前值为0美元；每股收益为-0.14美元，前值为-0.11美元，预期值为-0.17美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12204448120548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510498333","title":"Anavex Life Sciences Corp.盘中异动 股价大跌5.03%报8.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510498333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510498333?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:09","pubTimestamp":1739286556,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时09分，Anavex Life Sciences Corp.股票出现波动，股价急速跳水5.03%。截至发稿，该股报8.37美元/股，成交量14.9578万股，换手率0.18%，振幅3.69%。Anavex Life Sciences Corp.股票所在的生物技术行业中，整体跌幅为1.56%。Anavex Life Sciences Corp.公司简介：Anavex Life Sciences Corp 是一家临床阶段的生物制药公司，致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物，这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112309179881c461&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112309179881c461&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508468718","title":"Anavex Life Sciences Corp.盘中异动 早盘急速上涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508468718","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508468718?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:07","pubTimestamp":1738681663,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时07分，Anavex Life Sciences Corp.股票出现异动，股价快速拉升5.09%。Anavex Life Sciences Corp.股票所在的生物技术行业中，整体涨幅为1.01%。Anavex Life Sciences Corp.公司简介：Anavex Life Sciences Corp 是一家临床阶段的生物制药公司，致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物，这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204230743a2393058&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204230743a2393058&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.anavex.com","stockEarnings":[{"period":"1week","weight":-0.0986},{"period":"1month","weight":0.1667},{"period":"3month","weight":-0.3485},{"period":"6month","weight":-0.5898},{"period":"1year","weight":-0.6507},{"period":"ytd","weight":-0.0758}],"compareEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.1279},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.0404},{"period":"1year","weight":0.2988},{"period":"ytd","weight":0.0488}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Anavex Life Sciences Corp.成立于2004年1月23日，位于内华达州。是一家临床阶段的生物制药公司，致力于开发差异化疗法，将精准医学应用于高度未满足需求的中枢神经系统（CNS）疾病。该公司的重点是开发针对阿尔茨海默病、帕金森病、精神分裂症、神经发育、神经退行性疾病、包括雷特综合征在内的罕见疾病以及其他中枢神经系统（CNS）疾病的创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":-0.012212},{"month":2,"riseRate":0.454545,"avgChangeRate":0.117029},{"month":3,"riseRate":0.545455,"avgChangeRate":0.041572},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.059543},{"month":5,"riseRate":0.7,"avgChangeRate":0.033993},{"month":6,"riseRate":0.7,"avgChangeRate":0.16895},{"month":7,"riseRate":0.5,"avgChangeRate":-0.029973},{"month":8,"riseRate":0.4,"avgChangeRate":-0.036754},{"month":9,"riseRate":0.5,"avgChangeRate":0.010424},{"month":10,"riseRate":0.5,"avgChangeRate":-0.003565},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.028939},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.025909}],"exchange":"NASDAQ","name":"Anavex Life Sciences Corp.","nameEN":"Anavex Life Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Anavex Life Sciences Corp.(AVXL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Anavex Life Sciences Corp.(AVXL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Anavex Life Sciences Corp.,AVXL,Anavex Life Sciences Corp.股票,Anavex Life Sciences Corp.股票老虎,Anavex Life Sciences Corp.股票老虎国际,Anavex Life Sciences Corp.行情,Anavex Life Sciences Corp.股票行情,Anavex Life Sciences Corp.股价,Anavex Life Sciences Corp.股市,Anavex Life Sciences Corp.股票价格,Anavex Life Sciences Corp.股票交易,Anavex Life Sciences Corp.股票购买,Anavex Life Sciences Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Anavex Life Sciences Corp.(AVXL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Anavex Life Sciences Corp.(AVXL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}